T1	disease_or_phenotypic_feature 15 22	disease
T2	disease_or_phenotypic_feature 43 52	disorders
T3	chemical 109 119	biomarkers
T4	chemical 191 206	Tranexamic acid
T5	missed_chemical 208 211	TXA
T6	corrected_disease_or_phenotypic_feature 221 245	perioperative blood loss
T7	disease_or_phenotypic_feature 235 240	blood
T8	chemical 378 386	psoralen
T9	corrected_disease_or_phenotypic_feature 390 404	human hepatoma
T10	disease_or_phenotypic_feature 396 404	hepatoma
T11	disease_or_phenotypic_feature 551 570	Au25@ZIF-8@TiO2-ReP
T12	chemical 571 579	catalyst
T13	chemical 706 714	electron
T14	chemical 749 757	chemical
T15	chemical 762 772	biological
T16	disease_or_phenotypic_feature 813 824	blood-brain
T17	chemical 834 839	water
T18	chemical 886 896	metabolite
T19	chemical 909 917	chemical
T20	chemical 1002 1012	brain-lead
T21	disease_or_phenotypic_feature 1097 1109	stress ulcer
T22	chemical 1138 1149	proton-pump
T23	corrected_chemical 1138 1159	proton-pump inhibitor
T24	chemical 1150 1159	inhibitor
T25	chemical 1161 1172	histamine-2
T26	corrected_chemical 1161 1192	histamine-2 receptor antagonist
T27	chemical 1173 1192	receptor antagonist
T28	chemical 1182 1192	antagonist
T29	chemical 1197 1207	sucralfate
T30	chemical 1382 1391	oxidative
T31	disease_or_phenotypic_feature 1458 1471	liver disease
T32	disease_or_phenotypic_feature 1483 1502	portal hypertension
T33	chemical 1598 1612	growth hormone
T34	disease_or_phenotypic_feature 1668 1672	burn
T35	missed_chemical 1717 1723	agents
T36	disease_or_phenotypic_feature 1760 1769	mucositis
T37	missed_disease_or_phenotypic_feature 1778 1782	pain
T38	chemical 1797 1807	biological
T39	chemical 1933 1938	group
T40	disease_or_phenotypic_feature 1986 2010	hepatocellular carcinoma
T41	chemical 2011 2016	group
T42	disease_or_phenotypic_feature 2048 2053	NSCLC
T43	chemical 2152 2161	molecular
T44	disease_or_phenotypic_feature 2181 2186	NSCLC
T45	chemical 2254 2263	molecular
T46	chemical 2284 2292	lycorine
T47	disease_or_phenotypic_feature 2336 2362	non-small cell lung cancer
T48	disease_or_phenotypic_feature 2364 2369	NSCLC
T49	disease_or_phenotypic_feature 2501 2508	disease
T50	chemical 2534 2543	indicator
T51	disease_or_phenotypic_feature 2625 2634	infection
T52	disease_or_phenotypic_feature 2668 2675	disease
T53	disease_or_phenotypic_feature 2769 2774	tumor
T54	chemical 2877 2885	molecule
T55	chemical 3041 3053	mifepristone
T56	disease_or_phenotypic_feature 3096 3099	CSC
T57	chemical 3147 3159	enzalutamide
T58	disease_or_phenotypic_feature 3173 3176	CSC
T59	disease_or_phenotypic_feature 3258 3261	CRD
T60	chemical 3265 3279	micronutrients
T61	chemical 3335 3344	molecular
T62	disease_or_phenotypic_feature 3371 3401	post-traumatic stress disorder
T63	disease_or_phenotypic_feature 3403 3407	PTSD
T64	chemical 3459 3470	cholesterol
T65	disease_or_phenotypic_feature 3507 3522	prostate cancer
T66	disease_or_phenotypic_feature 3523 3527	(PCa
T67	disease_or_phenotypic_feature 3597 3605	disorder
T68	chemical 3665 3672	protein
T69	chemical 3688 3702	RNA-organizing
T70	disease_or_phenotypic_feature 3763 3770	amyloid
T71	chemical 3814 3824	biomarkers
T72	disease_or_phenotypic_feature 3915 3923	diseases
R1	treats Arg1:T4 Arg2:T6
R2	treats Arg1:T23 Arg2:T21
R3	treats Arg1:T5 Arg2:T6
R4	treats Arg1:T29 Arg2:T21
R5	treats Arg1:T26 Arg2:T21
R6	treats Arg1:T35 Arg2:T37
R7	treats Arg1:T35 Arg2:T36
R9	treats Arg1:T33 Arg2:T34	
T73	corrected_disease_or_phenotypic_feature 3096 3106	CSC growth
R10	treats Arg1:T55 Arg2:T73	
T74	missed_chemical 3027 3040	anti-GR agent
R11	treats Arg1:T74 Arg2:T73	
T75	missed_disease_or_phenotypic_feature 3173 3183	CSC growth
R12	causes_or_contributes_to Arg1:T57 Arg2:T75	
T76	missed_chemical 3133 3146	anti-AR agent
R13	causes_or_contributes_to Arg1:T76 Arg2:T75	
